secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2023-04-04T23:59:59+00:00
Accession:  0001104659-23-041237
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio terminates $50M ATM equity facility after selling 704K shares for $7.66M
--------------------------------------------------------------------------------

- Terminated ATM Sales Agreement with BofA Securities and ThinkEquity, effective April 9, 2023.
- Prior to termination, sold 704,000 shares at $10.88/share for gross proceeds of $7,659,520.
- No termination penalties incurred; no further shares will be offered under the agreement.
- Original agreement allowed up to $50M in common stock sales; only ~15% utilized.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465923041237/0001104659-23-041237-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465923041237/tm2311180d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-041237

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer